Research location

Shijiazhuang

China

Published trials143

Site observations160

Linked trials published143

Page1 / 3

Research activity in Shijiazhuang

China

CureCurrent currently publishes aggregate city-level research activity for this location: 143 trials and 160 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Shijiazhuang

143 linked trials · page 1 of 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusNCT07775404 · 2026-08-21 · 1 site observation

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisNCT07725939 · 2026-07-27 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553 · 2026-07-08 · 1 site observation

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 2 site observations

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416 · 2026-07-03 · 1 site observation

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in ChinaNCT07593248 · 2026-06-22 · 1 site observation

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseNCT07571161 · 2026-04-30 · 1 site observation

A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · 2026-02-09 · 1 site observation

Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabNCT07363642 · 2026-01-28 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementNCT06909773 · 2025-11-28 · 1 site observation

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaNCT07161388 · 2025-11-17 · 1 site observation

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C MutationNCT07198841 · 2025-11-03 · 1 site observation

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173 · 2025-10-22 · 1 site observation

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339 · 2025-10-20 · 2 site observations

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 2 site observations

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222 · 2025-09-17 · 1 site observation

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabNCT06862206 · 2025-07-11 · 1 site observation

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCNCT06962865 · 2025-06-30 · 1 site observation

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 1 site observation

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyNCT06862869 · 2025-04-30 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764 · 2025-02-21 · 1 site observation

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · 2024-06-17 · 1 site observation

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaNCT06471257 · 2024-06-17 · 2 site observations

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 2 site observations

Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation

A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe EmphysemaNCT06152107 · 2024-01-01 · 1 site observation

Mesenchymal Stem Cells Treatment for AIDS Patients at Late StageNCT05939167 · 2023-12-10 · 1 site observation

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNANCT05334277 · 2022-05-06 · 1 site observation

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 · 2025-09-30 · 1 site observation

NOT_YET_RECRUITING

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisNCT07483450 · 2025-07-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNCT07004335 · 2025-07-01 · 1 site observation

NOT_YET_RECRUITING

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)NCT06921486 · 2025-03-31 · 2 site observations

ACTIVE_NOT_RECRUITING

Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation

ACTIVE_NOT_RECRUITING

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885 · 2024-11-14 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06711900 · 2024-10-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation

ACTIVE_NOT_RECRUITING

Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.NCT06590740 · 2024-10-18 · 1 site observation

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26 · 1 site observation

ACTIVE_NOT_RECRUITING

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsNCT06529419 · 2024-08-30 · 1 site observation

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366 · 2024-07-22 · 1 site observation

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaNCT06465485 · 2024-02-28 · 2 site observations

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.